BACKGROUND: There is some evidence that systemic inflammation may be associated with survival in patients with prostate cancer; however, it is unclear whether this is independent of grade. We therefore investigated the role of inflammation-based prognostic scores, the modified Glasgow Prognostic Score (mGPS) and neutrophil lymphocyte ratio (NLR), and their associations with Gleason grade in patients with prostate cancer.
Introduction
Prostate cancer has now become the most frequently diagnosed cancer among men in Europe, with an estimated 382 000 new cases in 2008.
1 Age-standardised rates have increased rapidly over the past two decades in Europe and the United Kingdom, partly because of the increased use of PSA 2 testing and detection of a asymptomatic disease. 3 Although survival in patients with prostate cancer has improved in recent years, it is often difficult to differentiate patients who require potentially curative treatment from those who can be managed conservatively. Considerable effort has gone into identifying novel genetic and immunological biomarkers, however, these remain time consuming and not validated to be part of routine clinical practice. 4, 5 Therefore, in general, current clinical decisions are based on readily available tumour-related factors, including PSA levels, Gleason grade and clinical stage. 6 Although it is recognised that the development of cancer has a genetic basis, there is increasing recognition that the host inflammatory response is associated with the development and progression of cancers. [7] [8] [9] [10] In particular the systemic inflammatory response, as evidenced by an elevated C-reactive protein, has been shown to be independently associated with poor prognosis in many common solid tumours. 11 It is therefore of interest that the systemic inflammatory response, as measured by the modified Glasgow Prognostic Score (mGPS; a combination of C-reactive protein and albumin), has been shown to have prognostic value in operable and non-operable cancers independent of site. [11] [12] [13] [14] [15] It is also of interest that haematological components of the systemic inflammatory response, a combination of circulating neutrophil and lymphocyte counts to form the neutrophil lymphocyte ratio (NLR), have also been shown to be associated with survival in patients with cancer. 16, 17 The natural history and progression of prostate cancer is poorly understood, however, some evidence suggests an association between the activation of the systemic inflammatory response, as evidenced by raised C-reactive protein concentrations, and survival in patients with prostate cancer. 12, 13 However, these studies were small and it is unclear if these relationships remain in a large cohort, independent of Gleason grade, socioeconomic status and time of sampling. Therefore, the aim of the present study was to investigate the associations between inflammation-based prognostic scores (mGPS and NLR) and survival in a large cohort of patients with prostate cancer.
Materials and methods
From a cohort previously described, cancer patients in north Glasgow, UK, 14 who had a single blood sample taken between 1 January 2000 and 31 December 2007 for C-reactive protein, albumin, calcium as well as liver function tests, where available, were included in this study. The limit of detection of C-reactive protein was a concentration of o5 mg l À1 . 14 If more than one record was available for a patient then only the initial record was used. Patients were excluded if they did not have a complete set of identifying details (name, sex, date of birth and hospital number). 14 Prostate cancer diagnosis was established by linkage of the above biochemistry data and the Scottish Cancer Registry, also known as Scottish Morbidity Record 6 (SMR06). Linkage was by exact matching of patients' forename, surname and date of birth, followed by Soundex phonetic matching algorithm if initial exact matching was unsuccessful. Prostate cancer was defined as International Classification of Diseases (ICD), ICD-10 code C61. Only those patients who had a blood sample taken within a period of 2 years, before or after diagnosis of prostate cancer, were included in the analysis.
The Gleason grading system is known to be associated with prostatic cancer prognosis 15 and was used to describe tumour morphology. Gleason grade was extracted from the Scottish Cancer Registry where available. Date and cause of death was extracted through cancer registration patient based-linkage with General Register Office for Scotland death records.
Socioeconomic circumstances were measured by using the Scottish Index of Multiple Deprivation (SIMD)  2006. 18 This is a postcode-based measure of socioeconomic status derived by the postcode of residence. The SIMD score is based on detailed information on seven key domains including income and benefits, employment in working age population, health and healthcare utilisation, education attainment, access to services and transport, recorded crime rates and housing quality and overcrowding. 18 SIMD quintiles were used, 1 representing the least deprived quintile and 5 representing the most deprived quintile. This study was approved by the Research Ethics Committee, North Glasgow NHS Trust.
The mGPS and NLR were constructed as described in previous studies 16, 17, 19 (Table 1) . Follow-up was from date of incidence of cancer to the date of death or censor date (31 December 2008), whichever came first. Relative survival was used as a measure of cancer patients' survival. Relative survival has a key advantage over the cause-specific survival as it does not rely on the accurate classification of cause of death; instead it provides a measure of total prostate cancer-associated excess mortality.
Five years relative survival estimates were made by using age, gender and deprivation specific life tables provided by General Registrar Office (Scotland). These are available until 2007; so for the purposes of this study, the 2007 mortality rates were used for comparison as they are unlikely to be significantly different from those occurring in 2008. Relative survival estimates were made by age, deprivation, Gleason grade and mGPS, using the complete and hybrid approach (by STREL and STRS command in STATA). 20 STRS command in STATA implements the Ederer II method by default for the estimation of relative survival; however, we repeated the analyses using both the Ederer I and Hakulinen approaches. All three methods provided identical results, so the results presented in this study are based on the Ederer II Method. Using the full likelihood approach adjusted for age, deprivation and Gleason grade, the relative excess risk (RER) of death from prostate cancer was estimated. 21 This approach provides the estimate of excess risk of death due to cancer after adjusting for the background population mortality.
Patients who had missing NLR (n ¼ 188, 21%) were excluded from the excess risk estimation analyses. The lowest category was used as referent for the mGPS and all other categorical covariates. All analyses were conducted using STATA version 11 (Stata, College Station, TX, USA). Adherence to the proportional hazards assumption was investigated by plotting smoothed Schoenfeld residuals against time; no violations of the assumption were identified. We investigated the interactions between different variables in every multivariate model, but no significant interaction was found. All statistical tests were two tailed and statistical significance was taken as Po0.05.
Results
From the Glasgow Inflammation Outcome Study of 223 303 patients originally described, 27 301 patients Table 1 Systemic inflammation-based prognostic scores
Prognostic scores Score
The modified Glasgow Prognostic Score C-reactive protein p10 mg l À1 and albumin X35 g l were identified as having a diagnosis of cancer by Scottish Cancer Registry and a blood sample for C-reactive protein, albumin, white cells, neutrophil, lymphocyte and platelet counts taken between January 2000 and December 2007. 22 From this cohort, 897 patients who had a diagnosis of prostate cancer and had been sampled within 2 years before or after diagnosis, were included in this study. The majority, 575 (64%), were aged 75 or over. In all, 19% of patients lived in affluent areas (least deprived quintile of the Scottish population) and 34% in deprived areas (most deprived quintile of the Scottish population). The median followup from the cancer diagnosis was 2.5 years, and maximum 6.2 years.
Patients with an elevated mGPS (mGPS 1 and 2) were more likely to be 75 years or older (P ¼ 0.005) and have high-grade disease (Gleason 8-10) (Po0.001), but there was no association with socioeconomic circumstances based on SIMD (P ¼ 0.430). Similarly, patients with an elevated NLR (NLR score 1) were more likely to be older (P ¼ 0.022) and have a raised mGPS (Po0.001) but there was no significant association with socio-economic circumstances (P ¼ 0.338) or Gleason grade (P ¼ 0.074).
The individuals who had missing NLR were significantly older (2.3 years, P value o0.002, t ¼ 2.95) than those whose NLR data were available, whereas no significant differences were observed in distribution of Gleason grade (X 2 , P ¼ 0.08) and socioeconomic circumstances (X 2 , P ¼ 0.617). Furthermore, mean survival time was B6 months higher for those whose NLR was missing compared with those whose NLR was available.
Baseline characteristics of prostate cancer patients, before and after sampling, are shown in Table 2 . Patients who were sampled in the post-diagnosis group, compared with the pre-diagnosis group, were more likely to be older (Po0.001), have higher Gleason grade (Po0.001), come from less deprived areas (Po0.05), and have higher mGPS (Po0.01) and NLR (Po0.001) values. Patients who died in the post-diagnosis group, compared with the pre-diagnosis group, were more likely to be younger (Po0.001), have higher Gleason grade (Po0.001), and higher mGPS (Po0.05) and NLR (Po0.001) values. Because of differences in pre-and post-diagnosis sample characteristics, we conducted survival analyses for each separately.
Increasing age and high or unknown Gleason grade were associated with poorer 5-year relative survival (Tables 3 and 4 ). The 5-year relative survival of prostate cancer patients sampled before diagnosis was modelled using the full likelihood approach and is shown in Table 3 (Table 3) .
Five year relative survival of prostate cancer patients sampled after diagnosis modelled using the full likelihood Inflammation and survival from prostate cancer K Shafique et al (Table 5 ). In grade-specific analysis, NLR only showed a significant association with risk of death for unknown Gleason grade after adjustments for age, socioeconomic circumstances and mGPS (Table 5) . Similarly, age-specific analyses were also carried out and raised mGPS showed significantly higher risk of death among those with age o65 and 65-74 years at diagnosis. However, a nonsignificant increased risk of death was also observed among those aged 475 years (data not shown). Figure 1 shows the relative survival of high-grade (Gleason 8-10) prostate cancer patients based on the mGPS. Analysis of this subgroup showed that the mGPS was associated with reduced survival with a mGPS of 2 having 29% lower 3-year relative survival, when compared with those with an mGPS of 0.
Discussion
The results of the present study show that systemic inflammation-based prognostic scores-whether they are the mGPS or NLR-predict prostate cancer-specific survival. In particular, mGPS had significant prognostic value independent of time of sample, age at diagnosis, Gleason grade, socioeconomic status and NLR. We observed 35-40% lower 5-year relative survival among those with raised mGPS (mGPS ¼ 2) compared with the normal (mGPS ¼ 0) for those who were sampled either before or following diagnosis of prostate cancer.
In the present study, patients with high Gleason grade disease had a significantly raised mGPS compared with low-grade disease. In Gleason grade-specific analysis, a raised mGPS had significant associations with excess risk of death among patients with low, high grade and those with unknown Gleason grades, whereas NLR only showed significant association with poorer survival of unknown Gleason grade patients. In high-grade disease, patients with higher systemic inflammation (mGPS ¼ 2) had B200% excess risk of death in the first 5 years of diagnosis compared with those with low level of systemic inflammation (mGPS ¼ 0). Although there was no significant association between mGPS and survival in the intermediate Gleason grade, this could have been due to the small number of deaths in intermediate grade disease category (n ¼ 35). The largest effect of mGPS was Abbreviations: CI, confidence interval; mGPS, modified Glasgow Prognostic Score; NLR, neutrophil lymphocyte ratio. All estimates were adjusted for age at incidence, socioeconomic circumstances, mGPS and NLR. Patients with missing NLR were excluded from these analyses. All prostate cancer patients were included. Three years excess mortality modelled using the full likelihood approach. Estimates were adjusted for age, deprivation and neutrophil lymphocyte ratio Inflammation and survival from prostate cancer K Shafique et al seen in patients with low-grade prostate cancer (Gleason o7), a group for whom there is currently the greatest clinical uncertainty about their prognosis and management. Irrespective, taken together these results highlight the importance of systemic inflammation in relation to survival in patients with prostate cancer. In the present study patients with unknown Gleason grade had poorer relative survival even when compared with those with high-grade disease. These unknown Gleason grade patients may have had pre-terminal disease that was deemed metastatic and therefore histological staging was not considered appropriate. Interestingly, both mGPS and NLR were shown to have a prognostic value in this group of patients. Indeed, in those patients with unknown Gleason grade, those who had raised mGPS were twice as likely to die in the first 5 years following diagnosis as compared with those with lowest level of mGPS. This association remained significant even after adjusting for age, socioeconomic circumstances and NLR.
Prognostic Scores
The prognosis of prostate cancer patients is not well understood and clinicians treating cancer patients make decisions on the basis of individual's age, fitness, comorbidity, PSA, Gleason grade and disease stage. Novel genetic and immunological biomarkers have been identified but these, to date, have not been incorporated into routine clinical practice. 4, 5 The results of the present study show that systemic inflammation is of clinical importance and suggest the routine use of the mGPS as a cost effective, readily available tool for risk stratification in patients with prostate cancer.
Systemic inflammation measured by C-reactive protein has been associated with many chronic conditions including incidental and prevalent cardiovascular diseases. 23, 24 Given that prostate cancer is a disease of old age, patients in the present study may have co-morbid conditions leading the activation of the systemic inflammatory response. If this is the case, then differences in survival (estimated by conventional techniques using overall and cancer specific survival) between mGPS categories, may be explained by the distribution of co-morbidity between groups. However, in the present study, relative survival using a ratio of observed probability to expected probability of survival was used and thus adjusted for the background population mortality and provided mortality figures mainly based on cancer-associated deaths. Moreover, when adjusted for NLR, age, socioeconomic status and Gleason grade, patients with an elevated mGPS were significantly more likely to die at 5 years.
To our knowledge this is the first study, comparing the prognostic value of mGPS and NLR in prostate cancer patients and taking into account the background population mortality, age, Gleason grade and socioeconomic status. The present study has, however, a number of limitations. First, patients were selected on the basis of availability of C-reactive protein, albumin and calcium levels, therefore this cohort of patients might not be representative of all the prostate cancer patients diagnosed and treated in the north of Glasgow. Second, as C-reactive protein and other measurements were taken incidentally; there is a possibility that these patients might have had concurrent morbidity for which they were clinically investigated. However, this is unlikely to have had a major effect on our results, as we adjusted for background mortality using age-and deprivation-specific population mortality rates. Third, we have no information on the exact timing of treatment following diagnosis and it is possible that early treatment may have been responsible for increases in acute phase proteins. However, the relationship between inflammation and prognosis was similar in samples taken before and after diagnosis, suggesting that early treatment was not a significant confounding factor. Finally, we did not have the information on PSA or disease stage and patients may have had higher inflammatory status due to metastatic disease. However, previous studies have shown systemic inflammation to be associated with survival, independent of disease stage, for gastroesophageal, colorectal (including those with liver metastases), renal, breast and prostate cancers. 11, 25 Further work is required to investigate this relationship in a larger, representative sample of prostate cancer patients including information on other measures of prognosis (for example disease stage and PSA) and treatment.
Conclusion
In conclusion, the results of the present study indicate that systemic inflammation-based prognostic scores, mGPS and NLR, have prognostic value in prostate cancer patients. However, in terms of differentiating high risk from low risk patients, the mGPS appeared to be superior to the NLR.
